CDKN2B-AS1 and acute myeloid leukemia: At the molecular level, the knockdown of ANRIL expression resulted in a decrease in glucose uptake and the inhibition of AML cell maintenance through the targeting of adiponectin receptors in vitro and in vivo (121).